FDA clears Bolton's stent graft system for TAAs

Editorial Staff | | Cardiovascular Business | Vascular & Endovascular

The FDA has approved Bolton Medical's Relay thoracic stent graft with Plus delivery system to use as a minimally invasive treatment for thoracic aortic aneurysms (TAAs) and penetrating atherosclerotic ulcers.

The Relay system offers performance zones to provide varying levels of radial support and apposition; a four-step dual sheath delivery system; various sizes with lengths of 100 to 250 mm and diameters of 22 to 46 mm; and straight and tapered.

Bolton stent grafts have been available in Europe and other international markets since 2005. The U.S. pivotal study included 120 endovascular patients at 30 hospitals across the U.S.

Editorial Staff

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."